Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Imaging Studies I: CT and MRI01:14

Imaging Studies I: CT and MRI

Introduction: MRI and CT scans are crucial advancements in medical imaging techniques, playing a vital role in diagnosing conditions related to the gastrointestinal (GI) system. Each scan serves distinct purposes, targets specific areas, and requires unique nursing duties.
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A Case of Cecal‒Ascending Colon Cancer Achieved Complete Remission by Surgical Resection and Immune Checkpoint Inhibitor].

Gan to kagaku ryoho. Cancer & chemotherapy·2025
Same author

[A Case of Conversion Surgery after SOX+Nivolumab Treatment for Metastatic Gastric Cancer].

Gan to kagaku ryoho. Cancer & chemotherapy·2025
Same author

[A Case of MSI‒Stable Rectal Cancer with Para‒Aortic Lymph Node Metastasis Treated by Sequential Therapy with Standard Treatment and Immune Checkpoint Inhibitors].

Gan to kagaku ryoho. Cancer & chemotherapy·2025
Same author

A Case of Inflammatory Myofibroblastic Tumor in the Abdominal Wall with Anaplastic Lymphoma Kinase and Whole Exome Sequencing Analysis.

Surgical case reports·2025
Same author

Novel Artificial Intelligence Combining Convolutional Neural Network and Support Vector Machine to Predict Colorectal Cancer Prognosis and Mutational Signatures From Hematoxylin and Eosin Images.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2024
Same author

Rectal squamous cell carcinoma treated with neoadjuvant fluorouracil, oxaliplatin, cetuximab, and radiation: A case report of pathological complete response.

Medicine·2024

Related Experiment Video

Updated: Jul 7, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

[CPT-11 (Irinotecan)].

Shoichi Hazama1, Masaaki Oka

  • 1Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 19, 2008
PubMed
Summary

Genetic variations in the UGT1A1 gene influence chemotherapy drug CPT-11 toxicity. Investigating UGT1A1*28 may predict severe adverse events, improving patient treatment outcomes.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Drug Metabolism

Background:

  • Irinotecan (CPT-11) is activated to SN-38, which is inactivated by UGT1A enzymes.
  • UGT1A1 polymorphisms, specifically UGT1A1*28, affect gene expression and SN-38 inactivation.
  • Patient genetic profiles can personalize chemotherapy for increased efficacy and reduced toxicity.

Purpose of the Study:

  • To investigate the UGT1A1*28 polymorphism as a predictor of severe CPT-11 toxicity.
  • To explore the role of genetic profiling in tailoring chemotherapy regimens.

Main Methods:

  • Analysis of UGT1A1 gene polymorphisms, focusing on the number of TA repeats.
  • Correlation of UGT1A1*28 genotype with observed CPT-11 toxicities.
  • Review of existing literature on predictive markers for CPT-11 efficacy.

Related Experiment Videos

Last Updated: Jul 7, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

Main Results:

  • CPT-11 toxicities are linked to UGT1A1 gene polymorphisms affecting transcriptional efficiency.
  • The UGT1A1*28 variant was selected as a candidate for predicting severe toxicity.
  • Previous studies on predictive markers for CPT-11 efficacy remain controversial.

Conclusions:

  • UGT1A1*28 genotype may serve as a valuable biomarker for predicting CPT-11-induced toxicity.
  • Personalized chemotherapy based on pharmacogenetics can potentially optimize treatment outcomes.
  • Further research is warranted to validate predictive markers for CPT-11 efficacy and toxicity.